Enzymology and Molecular Biology of Carbonyl Metabolism 6

Volume 414 of the series Advances in Experimental Medicine and Biology pp 81-94

Class 1 and Class 3 Aldehyde Dehydrogenase Levels in the Human Tumor Cell Lines Currently Used by the National Cancer Institute to Screen for Potentially Useful Antitumor Agents

  • Lakshmaiah SreeramaAffiliated withDepartment of Pharmacology, University of Minnesota Medical School
  • , Norman E. SladekAffiliated withDepartment of Pharmacology, University of Minnesota Medical School

* Final gross prices may vary according to local VAT.

Get Access


With the ultimate goal of discovering new anticancer agents, the National Cancer Institute (NCI), through its Developmental Therapeutics Program, uses a semiautomatic procedure (Monks et al., 1991) to annually evaluate thousands of compounds for their ability to inhibit the growth of each of a panel of 60 human tumor cell lines (reviewed in Boyd and Pauli, 1995). The panel includes nine subpanels, each representing a specific tumor type, viz., leukemia, melanoma, and cancers of the brain, breast, colon, kidney, lung (non-small cell), ovary, and prostate, and each consisting of at least six tumor cell lines, except for the prostate cancer subpanel which consists of only two cell lines. The results of these tests, viz., GI50, TGI and LC50 values (the concentrations of an agent required to effect 50% growth inhibition, total growth inhibition and 50% cell-kill, respectively) have been, and are being, stored in an electronic database.